Trinity Biotech (TRIB)
(Delayed Data from NSDQ)
$1.83 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Income Statements
Fiscal Year end for Trinity Biotech PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 57 | 75 | 93 | 102 | 90 |
Cost Of Goods | 37 | 53 | 55 | 53 | 52 |
Gross Profit | 19 | 22 | 38 | 49 | 38 |
Selling & Adminstrative & Depr. & Amort Expenses | 47 | 39 | 31 | 49 | 62 |
Income After Depreciation & Amortization | -27 | -17 | 7 | 0 | -24 |
Non-Operating Income | 1 | 0 | 1 | 0 | 1 |
Interest Expense | 11 | 25 | 7 | 7 | 7 |
Pretax Income | -37 | -41 | 1 | -7 | -30 |
Income Taxes | 0 | 0 | 0 | -1 | -1 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -41 | 1 | -6 | -29 |
Extras & Discontinued Operations | 13 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -41 | 1 | -6 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -14 | 9 | 3 | -19 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 3 | 3 | 5 |
Income After Depreciation & Amortization | -27 | -17 | 7 | 0 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.66 | 6.75 | 5.33 | 5.25 | 5.09 |
Diluted EPS Before Non-Recurring Items | -3.37 | -5.25 | 1.75 | 3.75 | -0.15 |
Diluted Net EPS (GAAP) | -3.14 | -6.10 | 0.20 | -1.55 | -6.90 |
Fiscal Year end for Trinity Biotech PLC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 13.43 | 14.68 | 13.90 | 14.83 |
Cost Of Goods | NA | 8.86 | 10.40 | 8.87 | 9.26 |
Gross Profit | NA | 4.57 | 4.28 | 5.03 | 5.57 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.34 | 8.78 | 19.88 | 9.49 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.77 | -4.50 | -14.85 | -3.92 |
Non-Operating Income | NA | 0.57 | 0.39 | 0.06 | 0.15 |
Interest Expense | NA | 2.29 | 2.39 | 3.82 | 2.55 |
Pretax Income | NA | -5.50 | -6.50 | -18.61 | -6.32 |
Income Taxes | NA | 0.00 | 0.22 | -0.27 | -0.01 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.50 | -6.72 | -18.35 | -6.31 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 12.36 | 0.50 |
Net Income (GAAP) | NA | -5.50 | -6.72 | -5.99 | -5.81 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 7.67 | 7.67 | 7.66 | 7.63 |
Diluted EPS Before Non-Recurring Items | NA | -0.68 | -0.90 | -1.00 | -0.80 |
Diluted Net EPS (GAAP) | NA | -0.72 | -0.88 | -0.78 | -0.76 |